<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529617</url>
  </required_header>
  <id_info>
    <org_study_id>S59273</org_study_id>
    <nct_id>NCT03529617</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates</brief_title>
  <official_title>Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B
      between critically ill patients and non-critically ill (hematology) patients in an early and
      late exposure day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase IV, open label, non-randomized, monocenter pharmacokinetic study will be carried
      out in critically ill and non-critically ill (hematology) patients receiving multiple dose
      treatment with L-AmB.

      The pharmacokinetic exposure to liposomal amphotericin B in plasma, urine, BAL and ascitic
      fluid will be compared between the two population groups in an early and late exposure day.

      Correlating covariates will be identified to provide a rationale for optimal dosing strategy
      in critically ill patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Plasma exposure and PK parameters</measure>
    <time_frame>July 2020</time_frame>
    <description>To document and compare plasma exposure and PK parameters in an ICU vs. non ICU hematology patient cohort in the early and late phase of L-AmB treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Covariates</measure>
    <time_frame>July 2020</time_frame>
    <description>To document correlating covariates and to stimulate the pharmacokinetics of L-AmB to provide a rationale for optimal dosing strategy in critically ill patients.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Liposomal Amphotericin B</condition>
  <condition>Critically Ill Patients</condition>
  <arm_group>
    <arm_group_label>Critically ill patients</arm_group_label>
    <description>Patients admitted on ICU.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hematology patients</arm_group_label>
    <description>Patients admitted on the hematology ward.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>Plasma, urine, BAL and ascitic fluid sample collection.</description>
    <arm_group_label>Critically ill patients</arm_group_label>
    <arm_group_label>Hematology patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (plasma) Urine BAL (bronchoalveolar lavage) Ascitic fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. critically ill patients treated with L-AmB

          2. hematology patients treated with L-AmB
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with L-AmB

          -  Admitted to an ICU or Hematology ward

        Exclusion Criteria:

          -  DNR 2 or 3

          -  Pregnant or lactating women

          -  Previous documentation of intolerance/sensitivity to L-AmB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Spriet, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Van Daele, PharmD</last_name>
    <phone>+3216343264</phone>
    <email>ruth.vandaele@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabel Spriet, PharmD, PhD</last_name>
    <phone>+3216341261</phone>
    <email>isabel.spriet@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Van Daele, PharmD</last_name>
      <phone>+3216343264</phone>
      <email>ruth.vandaele@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

